Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.55 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.55 |
| ▸ | TTR | P02766 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | BACE1 | P56817 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20152947 | 0.93 | ALOX5 (0.49) | ALOX5OR51E2TTRMEN1KMT2A | |
| SCHEMBL5034496 | 0.87 | BACE1 (0.48) | TTRMEN1KMT2ABACE1KDM4E | |
| SCHEMBL20152931 | 0.86 | TTR (0.44) | ALOX5OR51E2TTRMEN1KMT2A | |
| SCHEMBL20152905 | 0.85 | TTR (0.43) | ALOX5OR51E2TTRMEN1KMT2A | |
| SCHEMBL3220836 | 0.81 | MEN1 (0.64) | ALOX5OR51E2MEN1KMT2ABACE1 | |
| SCHEMBL20152889 | 0.81 | ALOX5 (0.48) | ALOX5TTRKDM4EALDH1A1HSD17B10 | |
| SCHEMBL6035879 | 0.80 | CYP4F2 (0.50) | TTRMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL178369 | 0.77 | MAOB (0.52) | ALOX5TTRMEN1KMT2ABACE1 | |
| SCHEMBL6036250 | 0.77 | EGFR (0.55) | TTRMEN1KMT2ABACE1KDM4E | |
| SCHEMBL7332981 | 0.77 | HSD17B10 (0.63) | HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962674-B2 | Curcumin derivative | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2015-02-24 | — | — | US | disclosed |
| US-20100048901-A1 | NOVEL CURCUMIN DERIVATIVE | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2010-02-25 | — | — | US | disclosed |
| EP-2123637-A1 | NOVEL CURCUMIN DERIVATIVE | Tokyo Institute of Technology (JP) | 2009-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048901-A1 | NOVEL CURCUMIN DERIVATIVE | BACE1, APP, BACE2 | ALOX5 1890/4885OR51E2 4367/4885TTR 1425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.